Replies to post #1922 on Phio Pharmaceuticals Corp (PHIO)

[The Other Guy]

Might have to wait until tomorrow. I plan to listen again.

[The Other Guy]

Listening again to the conference call here are a few notes not necessarily found in the press release (we can cross check against the transcript of the cc when it is released):

Geert presenting highlights:
Right out the gate he tackled the Tang preferred share situation. Geert noted that Tang held 19% on March 31st and as of 5/13 held 7% as has been discussed in this forum. Geert said the completion of the selling by Tang "should substantially reduce the overhang and persistent selling pressure and should in turn provide for an attractive cap structure for our institutional investors."

Later he summarized by saying, RXI has a "clear vision and plan to become a major player in the biotech space."

Katlyn covered the financials. She said that the current shares outstanding was approximately 36M shares after Tangs selling. It should be around 39M shares when Tang is complete.

Look for an S-1 filing for additional funding. The terms are not determined at this time but it should be close.

Pamela covered R&D in great detail. The amount of information was too much to make note of. I suggest listening to the cc or reviewing the transcripts once they are complete. Some quick notes:

Dermal program has 3 studies. Two of the three are fully enrolled and the 3rd is expected to be fully enrolled in Q3 2015. The 6 month data from the third trial is the key data to look forward to. It is expected to be available in Q1 2016 but RXI may report on a subset of the data "before that time."

Far too much information on the SDR compounds to report. But the markets in just the cosmoceutical markets alone are huge:
Skin Lightening market is projected to be $23 Billion by 2020
Skin Rejuvenation market is to be 10 times that by 2020!
These numbers do not account for the pharmaceutical market potentials.

Optamology: RXI-109 IND for PI/II to be filed mid-2015 and could be initiated before year end.

I was interrupted during the Q&A playback but the most interesting question I recall from yesterday was the one about the SA article detailing the expected dilution.

In my opinion, once the Tang selling is complete and the additional funding terms are set RXII should see some nice PPS gains.